RxDoctor Payments Data

Jack Collazzo, MD

Gastroenterology · Bryn Mawr, PANPI 1891725891

Payments from drug & device makers

$3,783in general payments, 2019–2025

Across 185 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$290
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$262
  • Merck$215
  • Bayer$198
  • Paratek Pharmaceuticals, Inc.$123
  • plus $824 from 13 others

What the payments were for

  • Food & beverage$3,66397%
  • Education$1203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,783 in reported general payments places this provider in the 55th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$235,018
Medicare patients
827
Services billed
3,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XeljanzTofacitinib Citrate11$62,602
LinzessLinaclotide38$36,883
CreonLipase/Protease/Amylase13$26,883
Dexlansoprazole DrDexlansoprazole33$15,011
Mesalamine59$13,549
MotegrityPrucalopride Succinate23$11,980
Colesevelam Hcl58$9,609
Pantoprazole Sodium473$8,201
Esomeprazole Magnesium104$7,523
EliquisApixaban12$7,177
Lubiprostone17$4,953
Ursodiol17$4,607
DexilantDexlansoprazole13$4,010
MotofenDifenoxin Hcl/Atropine Sulfate22$3,282
Omeprazole211$2,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz, Eliquis$74$69,77923 claims
AbbVieLinzess, Creon$1,871$63,76651 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant$105$15,99036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Bryn Mawr

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →